Roche Plans to Use CQC’s Quantum Chemistry Software Platform EUMEN to Design Therapeutics to Treat Alzheimer’s
(FierceBiotech) Alzheimer’s disease has proven difficult to unravel, but Roche aims to tap into quantum computing to accelerate the process.
Through a multi-year partnership with the U.K.’s Cambridge Quantum Computing, the Swiss drugmaker’s task force plans to explore the nascent technology’s potential for designing and delivering new therapeutic compounds.
Roche will employ CQC’s quantum chemistry software platform EUMEN, a set of algorithms designed to simulate how atoms behave when absorbing energy, and used to form new pharmaceuticals and other specialty materials.
“For many years quantum computing has held out great promise for discovering new therapeutics that aid humanity in fighting some of the most devastating and damaging diseases,” CQC CEO Ilyas Khan said. “We are pleased that due to the careful and pioneering efforts of our research teams, some of this promise is starting to come to fruition.”